Fennec Pharmaceuticals Inc. - Common Stock (FENC)

Fennec Pharmaceuticals (NASDAQ:FENC) reported third-quarter net product sales of $19.4 million, up 56% from a year earlier, as use of its hearing-protection drug PEDMARK expanded among new and existing customers. Chief Executive Officer Jeff Hackman said the company benefited from a larger sales or

Record infusions and a larger sales force lifted quarterly profitability.

Adherex Technologies (NASDAQ:FENC), operating as Fennec Pharmaceuticals, reported second-quarter 2026 net product sales of $17.1 million, up approximately 78% from $9.7 million in the prior-year period, as demand for its PEDMARK therapy continued to rise. Chief Executive Officer Jeff Hackman said t

Fennec Pharmaceuticals (NASDAQ:FENC) executives outlined the company’s commercial strategy for PEDMARK, its sodium thiosulfate product used to prevent cisplatin-related hearing loss, during a fireside chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference. Ram Selvaraju, managing dir

Fennec (FENC) Q1 2026 Earnings Call Transcript

Adherex Technologies (NASDAQ:FENC) executives said Fennec Pharmaceuticals entered 2026 with stronger commercial momentum for PEDMARK, reporting higher first-quarter sales, positive operating cash flow and early signs that recent sales force investments are increasing demand. On the company’s first-

This water solutions provider serves both consumers and businesses through recurring sales and a broad portfolio of regional brands.

Euronet Worldwide runs a global payments platform, providing transaction processing and money transfer solutions across diverse markets.

This technology firm delivers IT infrastructure and managed solutions to major enterprises across multiple global industries.

Fennec Pharmaceuticals reported mixed Q2 2025 results, missing revenue estimates by 0.6% and posting a wider EPS loss. PEDMARK® growth and new accounts drove optimism despite financial underperformance.

Stocks extended last week's losses on Monday as concerns over the U.S. economy continue to weigh on the market. The Nasdaq 100 saw the steepest declines, with Tesla, Inc. (NASDAQ:TSLA) and Palantir Technologies, Inc.

FENC stock results show that Fennec Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.

These dirt cheap stocks under $10 have the potential to rise rapidly and create fortunes for bold investors.

FENC stock results show that Fennec Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.